Efficacy of a feline leukemia virus vaccine in a natural exposure challenge.
A commercial feline leukemia virus (FeLV) vaccine was evaluated in a natural exposure system. All kittens were negative for FeLV antigen on two enzyme-linked immunosorbent assay (ELISA) tests and one indirect immunofluorescence antibody (IFA) test before vaccination or exposure. Twenty-three kittens were vaccinated subcutaneously at nine and 12 weeks of age. The vaccinated kittens and 14 unvaccinated littermates were housed in an infected environment starting at 14 weeks. The kittens were exposed for 24 weeks by living in a large room with one feline leukemia virus-positive, asymptomatic adult cat for each five kittens. Sixty-four percent of the unvaccinated kittens and 70% of the vaccinated kittens became infected as determined by ELISA. Forty-three percent of unvaccinated kittens and 39% of vaccinated kittens died. There was no difference between the infection and mortality of vaccinated kittens that developed antibodies to anti-FeLV glycoprotein 70-envelope antigen and those that did not. Consideration should be given to evaluation of feline leukemia virus vaccines using "street" virus in a natural exposure system.
Legendre
A M
AM
Dept. of Urban Practice, College of Veterinary Medicine, University of Tennessee, Knoxville 37901-1071.
Mitchener
K L
KL
Potgieter
L N
LN
D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis; D000956:Antigens, Viral / Q000032:analysis; D002371:Cat Diseases / Q000517:prevention & control*; D002415:Cats; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005455:Fluorescent Antibody Technique; D007938:Leukemia / Q000517:prevention & control / Q000662:veterinary*; D005256:Leukemia Virus, Feline / Q000276:immunology*; D008297:Male; D013047:Specific Pathogen-Free Organisms; D014611:Vaccination / Q000662:veterinary*; D014765:Viral Vaccines
D000914:Antibodies, Viral; D000956:Antigens, Viral; D014765:Viral Vaccines